Evaluation of the hypoglycaemic and antioxidant effects of submerged Ganoderma lucidum cultures in type 2 diabetic rats

References

• Bach EE, Hi EMB, Martins AMC, Nascimento PAM, Wadt NSY. 2018. Hypoglicemic and hypolipedimic effects of Ganoderma lucidum in streptozotocin-induced diabetic rats. Med (Basel). 5(3):78.
   PubMedGoogle Scholar
• Boyko EJ, Magliano D, Shaw JE. 2007. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the women’s health initiative observational study: response to Song et al. Diabetes Care. 30(11):e110. author reply e111.
   PubMedGoogle Scholar
• Chang M-Y, Tsai G-J, Houng J-Y. 2006. Optimization of the medium composition for the submerged culture of Ganoderma lucidum by Taguchi array design and steepest ascent method. Enzyme Microb Technol. 38(3–4):407–414.
   Web of Science ®Google Scholar
• Dahlqvist A. 1968. Assay of intestinal disaccharidases. Anal Biochem. 22(1):99–107.
   PubMed Web of Science ®Google Scholar
• Erickson RH, Zakim D, Vessey DA. 1978. Preparation and properties of a phospholipid-free form of microsomal UDP-glucuronyltransferase. Biochem. 17(18):3706–3711.
   PubMed Web of Science ®Google Scholar
• Girometta C. 2019. Antimicrobial properties of fomitopsis officinalis in the light of its bioactive metabolites: a review. Mycol. 10(1):32–39.
   PubMedGoogle Scholar
• Glinghammar B, Rafter I, Lindström AK, Hedberg JJ, Andersson HB, Lindblom P, Berg AL, Cotgreave I. 2009. Detection of the mitochondrial and catalytically active alanine aminotransferase in human tissues and plasma. Int J Mol Med. 23(5):621–623.
   PubMed Web of Science ®Google Scholar
• He CY, Li WD, Guo SX, Lin SQ, Lin ZB. 2006. Effect of polysaccharides from Ganoderma lucidum on streptozotocin-induced diabetic nephropathy in mice. J Asian Nat Prod Res. 8(8):705–711.
   PubMed Web of Science ®Google Scholar
• Heymann AD, Cohen Y, Chodick G. 2012. Glucose-6-phosphate dehydrogenase deficiency and type 2 diabetes. Diabetes Care. 35(8):e58.
   PubMedGoogle Scholar
• Jia J, Zhang X, Hu Y-S, Wu Y, Wang Q-Z, Li -N-N, Guo Q-C, Dong X-C. 2009. Evaluation of in vivo antioxidant activities of Ganoderma lucidum polysaccharides in STZ-diabetic rats. Food Chem. 115(1):32–36.
   Web of Science ®Google Scholar
• Jiang X, Chang H, Zhou Y. 2015. Expression, purification and preliminary crystallographic studies of human glutamate oxaloacetate transaminase 1 (GOT1). Protein Expr Purif. 113:102–106.
   PubMed Web of Science ®Google Scholar
• Ma H-T, Hsieh J-F, Chen S-T. 2015. Anti-diabetic effects of Ganoderma lucidum. Phytochem. 114:109–113.
   PubMed Web of Science ®Google Scholar
• Manna P, Ghosh J, Das J, Sil PC. 2010. Streptozotocin induced activation of oxidative stress responsive splenic cell signaling pathways: protective role of arjunolic acid. Toxicol Appl Pharmacol. 244(2):114–129.
   PubMed Web of Science ®Google Scholar
• Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G. 1998. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes. 47(2):224–229.
   PubMed Web of Science ®Google Scholar
• Murat JC, Serfaty A. 1974. Simple enzymatic determination of polysaccharide (glycogen) content of animal tissues. Clin Chem. 20(12):1576–1577.
   PubMed Web of Science ®Google Scholar
• Neyrinck AM, Pachikian B, Taminiau B, Daube G, Frederick R, Cani PD, Bindels LB, Delzenne NM. 2016. Intestinal sucrase as a novel target contributing to the regulation of glycemia by prebiotics. PLoS One. 11(8):e0160488.
   PubMed Web of Science ®Google Scholar
• Ogbole OO, Nkumah AO, Linus AU, Falade MO. 2019. Molecular identification, in vivo and in vitro activities of Calvatia gigantea (macro-fungus) as an antidiabetic agent. Mycol. 10(3):166–173.
   PubMedGoogle Scholar
• Olokoba AB, Obateru OA, Olokoba LB. 2012. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 27(4):269–273.
   PubMedGoogle Scholar
• Pan D, Zhang D, Wu J, Chen C, Xu Z, Yang H, Zhou P. 2013. Antidiabetic, antihyperlipidemic and antioxidant activities of a novel proteoglycan from ganoderma lucidum fruiting bodies on db/db mice and the possible mechanism. PLoS One. 8(7):e68332.
   PubMed Web of Science ®Google Scholar
• Raza H, Prabu SK, John A, Avadhani NG. 2011. Impaired mitochondrial respiratory functions and oxidative stress in streptozotocin-induced diabetic rats. Int J Mol Sci. 12(5):3133–3147.
   PubMed Web of Science ®Google Scholar
• Seto SW, Lam TY, Tam HL, Au AL, Chan SW, Wu JH, Yu PH, Leung GP, Ngai SM, Yeung JH, et al. 2009. Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomed. 16(5):426–436.
   PubMed Web of Science ®Google Scholar
• Shieh YH, Liu CF, Huang YK, Yang JY, Wu IL, Lin CH, Li SC. 2001. Evaluation of the hepatic and renal-protective effects of Ganoderma lucidum in mice. Am J Chin Med. 29(3–4):501–507.
   PubMed Web of Science ®Google Scholar
• Sloop KW, Showalter AD, Cox AL, Cao JX, Siesky AM, Zhang HY, Irizarry AR, Murray SF, Booten SL, Finger EA, et al. 2007. Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease. J Biol Chem. 282(26):19113–19121.
   PubMed Web of Science ®Google Scholar
• Teng BS, Wang CD, Zhang D, Wu JS, Pan D, Pan LF, Yang HJ, Zhou P. 2012. Hypoglycemic effect and mechanism of a proteoglycan from ganoderma lucidum on streptozotocin-induced type 2 diabetic rats. Eur Rev Med Pharmacol Sci. 16(2):166–175.
   PubMed Web of Science ®Google Scholar
• Vitak TY, Wasser SP, Nevo E, Sybirna NO. 2015. The effect of the medicinal mushrooms Agaricus brasiliensis and Ganoderma lucidum (Higher basidiomycetes) on the erythron system in normal and streptozotocin-induced diabetic rats. Int J Med Mushrooms. 17(3):277–286.
   PubMed Web of Science ®Google Scholar
• Wachtel-Galor S, Yuen J, Buswell JA, Benzie IFF. 2011. Ganoderma lucidum (Lingzhi or Reishi): A medicinal mushroom. In: nd, Benzie IFF, Wachtel-Galor S, editors. Herbal medicine: biomolecular and clinical aspects. Boca Raton (FL): CRC Press/Taylor & Francis.
   Google Scholar
• Wang CD, Teng BS, He YM, Wu JS, Pan D, Pan LF, Zhang D, Fan ZH, Yang HJ, Zhou P. 2012. Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice. Br J Nutr. 108(11):2014–2025.
   PubMed Web of Science ®Google Scholar
• Wolosin JD, Edelman SV. 2000. Diabetes and the gastrointestinal tract. Clin Diabetes. 18(4):148.
   Google Scholar
• Wu Y, Ding Y, Tanaka Y, Zhang W. 2014. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 11(11):1185–1200.
   PubMed Web of Science ®Google Scholar
• Xiao C, Wu QP, Cai W, Tan JB, Yang XB, Zhang JM. 2012. Hypoglycemic effects of Ganoderma lucidum polysaccharides in type 2 diabetic mice. Arch Pharm Res. 35(10):1793–1801.
   PubMed Web of Science ®Google Scholar
• Zheng J, Yang B, Yu Y, Chen Q, Huang T, Li D. 2012. Ganoderma lucidum polysaccharides exert anti-hyperglycemic effect on streptozotocin-induced diabetic rats through affecting β-cells. Comb Chem High Throughput Screen. 15(7):542–550.
   PubMed Web of Science ®Google Scholar